[185 Pages Report] The Cancer/Tumor Profiling Market size was estimated at USD 10.79 billion in 2023 and expected to reach USD 12.77 billion in 2024, at a CAGR 18.74% to reach USD 35.94 billion by 2030.

Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient’s tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.

Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, reflecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.

The market dynamics represent an ever-changing landscape of the Cancer/Tumor Profiling Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Increasing adoption of biomarkers to treat cancer patients
  • Availability of government and global organizations' initiatives for devising cancer diagnosing methods
  • Surging preference for personalized medicines for cancer treatment
• Market Restraints
  • High capital investment in cancer/tumor profiling instruments and services
• Market Opportunities
  • Emergence of next-generation sequencing and advancements in tumor profiling
  • Improvements in point-of-care diagnostic technologies to improve cancer detection
• Market Challenges
  • Low biomarker discovery-to-approval ratio

• Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers

  Immunoassays dominate the technology segment of the cancer tumor profiling market owing to rising applications in conducting tumor profiling on a large scale, as they aid in measuring the presence and concentration of analytes in a sample. In situ hybridization (ISH), including fluorescence in-situ hybridization (FISH) and chromogenic in situ hybridization (CISH), uses labeled complementary DNA or RNA strands to localize a specific DNA or RNA sequence on a chromosome or section of tissue (in-situ) fixed on a slide. FISH profiling is less time-consuming than conventional approaches and assists in easy chromosomal microdeletion, amplification, and translocation. Mass spectrometry-based cancer/tumor profiling is increasingly used in cancer research to detect subtle changes in proteome and metabolome. In contrast, microarrays are widely used to understand cancer cells' genetic and epigenetic makeup, and they are utilized to identify small genetic changes in tumor cells. The development of next-generation sequencing (NGS) helps in effectively exploring genetic alterations in various cancers and identifying several genetic or epigenetic variants to develop new biomarkers for early diagnosis of the disease. Polymerase chain reaction (PCR) is used to look for specific changes in a gene or chromosome, which helps find and diagnose a genetic condition or a disease, such as cancer. Moreover, technological advances in imaging and biochemical processes that allow earlier detection of a metastatic lesion could yield higher success rates in cancer therapy.

• Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation

  Genomic biomarkers can be termed as the measurement of the expression of a gene, the gene function, or the gene regulation, and testing can determine whether someone's cancer has an estimated glomerular filtration rate (EGFR) gene mutation that can be treated with an EGFR inhibitor and also helps study a new cancer treatment in a clinical trial. An ideal cancer biomarker can be a protein or protein fragment that is easy to detect in the patient's blood or urine except for a healthy patient. In addition, there are many cancer biomarkers, and they separately work within the body and react differently to treatments. These cancer biomarkers can also include gene mutations (changes), gene rearrangements, extra copies of genes, missing genes, and several other molecules.

• Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification

  Cancer/tumor profiling has become an integral part of disease management on multiple levels for breast cancer. Genetic testing identifies hereditary cancer syndromes in patients with a family history of malignancies and contributes to successful breast cancer prevention. Molecular profiling of colorectal cancer (CRC) has the advantage of providing essential information on the pathogenesis of cancer and also about the targeted therapy. The landscape of metastatic CRC (mCRC) treatment is changing with an understanding of its heterogeneity and molecular blueprint, although chemotherapy remains the backbone of treatment. Common genetic mutations in lung cancer, such as estimated glomerular filtration rate (EGFR), RET, MET, BRAF, and anaplastic lymphoma kinase (ALK), can be detected, which leads to offering targeted therapy to the patient. Molecular predictive tests based on gene expression profiling (GEP) of cutaneous melanoma (CM) are susceptible and have the potential to predict biological behavior. Moreover, cancer/tumor profiling of prostate cancer has more recently emerged as a reliable method for predictive modeling and clinical risk stratification. Integrative genomic profiling of prostate tumors has provided comprehensive information and novel discoveries that improve understanding of the disease in the new era of precision medicine.

• Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time

  Cancer/tumor profiling has significantly advanced clinical oncology by identifying therapeutic targets and molecular biomarkers, guiding the personalization of cancer treatment with remarkably improved outcomes for numerous common and rare tumor entities. Cancer/tumor profiling is normally used in developing precision medicine that suits a patient's genetic makeup to improve healing and recovery time. The upgradation of biomarker discovery and development with the application of new and complex technologies and more clinical applications of biomarkers improves diagnosis, prognosis, and disease monitoring. Researchers are touting more precision-based and targeted techniques to streamline cancer treatment, which propels rapid diagnostics providers to seek highly sophisticated cancer profiling approaches. Genome-based prognostic biomarkers are used in the prognosis of several cancer types at clinical stages and also help develop drugs and therapies. Cancer/tumor profiling is also helpful in cancer screening and can help in early detection, management, and, potentially, curing cancer. In addition, cancer/tumor profiling offers the sensitive and accurate detection of biomarkers and has a reliable approach for noninvasive disease diagnosis and treatment response monitoring.

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Cancer/Tumor Profiling Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Cancer/Tumor Profiling Market.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cancer/Tumor Profiling Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The value chain of the Cancer/Tumor Profiling Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

The pricing analysis comprehensively evaluates how a product or service is priced within the Cancer/Tumor Profiling Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Cancer/Tumor Profiling Market.

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Cancer/Tumor Profiling Market.

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Cancer/Tumor Profiling Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

The trade analysis of the Cancer/Tumor Profiling Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

The regulatory framework analysis for the Cancer/Tumor Profiling Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer/Tumor Profiling Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer/Tumor Profiling Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers

  Agilent Technologies Inc. has entered into a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore to accelerate translational cancer research on Asian-prevalent cancers over the next two years. As part of this agreement, Agilent has supplied an automated NGS library preparation platform, enabling investigations into the genomic details specific to Asian cancer cohorts. [Published On: 2023-09-19]

• Sophia Genetics, Agilent Partner on Cancer Analysis Product

  Sophia Genetics, a leader in data-driven medicine, has recently announced a long-term partnership with Agilent Technologies, allowing them to develop a new cancer analysis product. This new product will enable clinicians to use patient’s genomic profiling information for smarter and more efficient care decisions. Through this endeavor, both companies are working towards making personalized cancer treatments faster and more accessible. With their product, doctors can move from the traditional trial-and-error approach of prescribing drugs to one tailored and precisely matches therapeutic agents to the tumor's genetics. The longer-term research is underway as well, which could help serve as an important resource for future cancer studies. [Published On: 2023-03-14]

• Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer

  Point32Health and Foundation Medicine have recently taken a major step forward in providing comprehensive genomic profiling for members with advanced cancer. By expanding access to this technology, individuals will now receive tailored treatments that can increase their chances of responding to the therapy needed for successful treatment outcomes. This initiative will increase human-recoded data levels and provide a more personalized approach to cancer treatments, leading the way in providing the best possible care for those fighting the disease. With Foundation Medicine's mission to accelerate precision medicine and Point32Health's dedication to making complex molecular information accessible, these two organizations are positioned as game changers when advancing cancer treatments. [Published On: 2023-03-02]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer/Tumor Profiling Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., Nonacus Limited, GenScript Biotech Corporation, Tempus Labs Inc., Thermo Fisher Scientific Inc., Hologic, Inc., 4basecare Onco Solutions Private Limited, Personalis, Inc., Merck KGaA, Exact Sciences Corporation, Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Guardant Health, Inc., Sysmex Corporation, Agendia, Inc., Paragon Genomics, Inc., F. Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc., NanoString Technologies, Inc., Predictive Oncology Inc., IMBdx, Inc., Perthera, Inc., GENINUS Inc., Genomic Life, ACT Genomics Co., Ltd. by Prenetics Global Limited, BostonGene Corporation, Caris Life Sciences, Strand Life Sciences, Neogenomics, Inc., Agilent Technologies, Inc., Oncompass Medicine Hungary Kft., and OncoDNA S.A..

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Immunoassays
  • In-Situ Hybridization
  • Mass Spectrometry
  • Microarrays
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
• Biomarker Type
  • Genomic Biomarker
  • Protein Biomarker
• Cancer Type
  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Prostate Cancer
• Application
  • Biomarker Discovery
  • Clinical Application
  • Diagnostics
  • Personalized Medicine
  • Prognostics
  • Research
  • Screening
  • Treatment & Monitoring

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?